EMA grants orphan drug designation to aTyr Pharma for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris

Release Date: 12-Apr-2017

European Medicine Agency has granted orphan drug designation to aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, for company’s novel product, Resolarisandtrade; for the treatment of limb girdle muscular dystrophy (LGMD) patients.
EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. Orphan designation is conferred following a positive opinion by the EMA's Committee for Orphan Medicinal Products (COMP).
“Global Orphan Drug Clinical Pipeline Insight” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.
For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com          

Need custom market research solution? We can help you with that too.